

# Role of erythropoietin receptor signaling in Friend virus–induced erythroblastosis and polycythemia

Ji Zhang, Mindy S. Randall, Melanie R. Loyd, Weimin Li, Rachel L. Schweers, Derek A. Persons, Jerold E. Rehg, Constance T. Noguchi, James N. Ihle, and Paul A. Ney

**Friend virus is an acutely oncogenic retrovirus that causes erythroblastosis and polycythemia in mice. Previous studies suggested that the Friend virus oncoprotein, gp55, constitutively activates the erythropoietin receptor (EPOR), causing uncontrolled erythroid proliferation. Those studies showed that gp55 confers growth factor independence on an interleukin-3 (IL-3)–dependent cell line (Ba/F3) when the EPOR is coexpressed. Subsequently, we showed that a truncated form of the stem-cell kinase receptor (sf-STK)**

**is required for susceptibility to Friend disease. Given the requirement for sf-STK, we sought to establish the in vivo significance of gp55-mediated activation of the EPOR. We found that the cytoplasmic tyrosine residues of the EPOR, and signal transducer and activator of transcription-5 (STAT5), which acts through these sites, are not required for Friend virus–induced erythroblastosis. The EPOR itself was required for the development of erythroblastosis but not for gp55-mediated erythroid proliferation. Interestingly, the mu-**

**rine EPOR, which is required for gp55-mediated Ba/F3-cell proliferation, was dispensable for erythroblastosis in vivo. Finally, gp55-mediated activation of the EPOR and STAT5 are required for Friend virus–induced polycythemia. These results suggest that Friend virus activates both sf-STK and the EPOR to cause deregulated erythroid proliferation and differentiation. (Blood. 2006;107:73-78)**

© 2006 by The American Society of Hematology

## Introduction

Friend disease is a multistage viral disease in mice.<sup>1-3</sup> In the initial stage of Friend disease, expression of the viral oncoprotein, gp55, causes uncontrolled erythroid proliferation and erythroblastosis. Erythroblastosis is a condition characterized by the rapid accumulation of immature erythroid cells leading to acute splenic enlargement. In the later stages of Friend disease, retroviral integrations in *Sfp1*, *p53*, and *Nfe2* cause progression to erythroleukemia. Friend virus is a complex of 2 viruses, Friend murine leukemia virus and spleen focus-forming virus (SFFV).<sup>4,5</sup> SFFV encodes a mutant envelope protein, gp55, which is necessary and sufficient for the erythroblastosis stage of the disease.<sup>6</sup> There are 2 strains of Friend virus, an anemia-inducing strain (FVA) and a polycythemia-inducing strain (FVP).<sup>1,7</sup> The amino acids responsible for this phenotypic difference have been localized to the transmembrane domain of gp55 (gp55<sub>A</sub> and gp55<sub>P</sub>).<sup>8</sup> Previously, it was shown that gp55<sub>P</sub> could interact with the erythropoietin receptor (EPOR) and support proliferation of the interleukin-3 (IL-3)–dependent cell line Ba/F3.<sup>9</sup> Based on this observation, it was proposed that Friend virus causes erythroblastosis through constitutive activation of the EPOR.

Additional insights into the mechanism of action of Friend virus have been provided by host factors that confer resistance or susceptibility to Friend disease. *Fv1* and *Fv4* confer resistance to

Friend disease through interference with the virus life cycle or interference with virus binding to the ecotropic receptor, respectively.<sup>10,11</sup> *Fv2* confers susceptibility through its effect on gp55-mediated erythroid proliferation.<sup>12,13</sup> Strains of mice that are *Fv2* resistant (*Fv2*<sup>rr</sup>) fail to develop either the initial erythroblastosis or late erythroleukemic phases of Friend disease. *Fv2* has been identified as the stem-cell kinase receptor (STK).<sup>14</sup> Strains of mice that are *Fv2* susceptible (*Fv2*<sup>ss</sup>) express a truncated form of STK (sf-STK). sf-STK encodes the transmembrane and tyrosine kinase domains of STK but not the extracellular domain.<sup>15</sup> Targeted disruption of *Stk* confers resistance to Friend disease, and enforced expression of sf-STK confers susceptibility to Friend disease in *Fv2*<sup>rr</sup> strains of mice.<sup>14</sup> Thus, sf-STK is both necessary and sufficient for susceptibility to Friend disease at the *Fv2* locus.

The essential role of sf-STK in gp55-mediated erythroid proliferation contrasts with the uncertain significance of gp55-mediated activation of the EPOR. One possibility is that gp55 facilitates an interaction between sf-STK and the EPOR. The receptor tyrosine kinase KIT interacts with the EPOR at the erythroid colony-forming unit (CFU-E) stage of erythroid development.<sup>16,17</sup> By analogy to KIT, an interaction between sf-STK and the EPOR could cause phosphorylation of the EPOR and support erythroid proliferation and differentiation. Alternatively, gp55

From the Departments of Biochemistry, Experimental Hematology, and Pathology, St Jude Children's Research Hospital, Memphis, TN; Integrated Program in Biomedical Science, University of Tennessee Health Science Center, Memphis; and the Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

Submitted May 2, 2005; accepted August 29, 2005. Prepublished online as *Blood* First Edition Paper, September 20, 2005; DOI 10.1182/blood-2005-05-1784.

Supported by National Institutes of Health grant RO1 CA084214 (P.A.N.), National Institutes of Health Cancer Center support grant P30 CA21765, and the American, Lebanese, and Syrian Associated Charities.

J.Z. and M.S.R. contributed equally to this study.

An Inside *Blood* analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

**Reprints:** Paul A. Ney, Department of Biochemistry, Rm 4064, Thomas Tower, St Jude Children's Research Hospital, 332 North Lauderdale St, Memphis, TN 38105-2794; e-mail: paul.ney@stjude.org.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2006 by The American Society of Hematology

could activate sf-STK and the EPOR independent of one another. In that case, gp55-mediated activation of the EPOR might primarily affect erythroid-cell survival and differentiation. Consistent with the latter hypothesis, our studies show that the EPOR is not essential for Friend virus–induced erythroid proliferation but is required for the development of polycythemia.

## Materials and methods

### Mice

Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup>, EporH, EporHM, Tg(GFP), and Epor<sup>-/-</sup>;Tg(EPOR) mouse strains were previously described.<sup>18-21</sup> EporH and EporHM are targeted strains that express truncated forms of the EPOR lacking the distal 7, or all 8, cytoplasmic tyrosine residues, respectively.<sup>19</sup> Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup> mice contain targeted mutations of the *Stat5a* and *Stat5b* genes.<sup>18</sup> Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup>, EporH, and EporHM mice were backcrossed to a Friend virus sensitive background (Balb/cByJ). Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup> mice were maintained on a RAG1-deficient background to prevent development of autoimmune disease associated with signal transducer and activator of transcription-5 (STAT5) deficiency.<sup>22,23</sup> Epor<sup>-/-</sup>;Tg(EPOR) mice contain an 80-kb human EPOR transgene, which complements targeted mutation of the murine *Epor* gene.<sup>21</sup> To obtain Epor<sup>-/-</sup>;Tg(EPOR) mice on a Friend virus–susceptible background, we mated them with Balb/cByJ Epor<sup>+/-</sup> mice. Incidentally, the *Epor* mutation in the Epor<sup>+/-</sup> mice was from a different strain.<sup>24,25</sup> Tg(GFP) mice contain a green fluorescent protein (GFP) transgene, linked to the H-2K<sup>b</sup> promoter, which is widely expressed in hematopoietic cells.<sup>20</sup> C57BL6/J (*Fv2<sup>tr</sup>*) mice were backcrossed to a Balb/cByJ background through the use of marker-assisted accelerated crossing (MAX-BAX; Charles River Laboratories, Wilmington, MA) to generate a new congenic mouse strain C.B6-*Fv2<sup>tr</sup>*. All studies were performed under an animal protocol approved by the Institutional Animal Care and Use Committee of Saint Jude Children's Research Hospital, Memphis, TN.

### Friend virus

FVA (gift from M. Bondurant) was passaged once in Balb/cByJ mice and the plasma frozen in small aliquots. We diluted the plasma 1:15 in Iscove modified Dulbecco medium (IMDM) and injected 0.2 mL into the tail vein. FVP was harvested from the supernatant of FP63 producer cells (gift from A. Bernstein). We diluted the supernatant 1:5 in IMDM and injected 0.2 mL into the tail vein. Two weeks after infection with FVA or FVP, we humanely killed the mice and harvested the spleens for analysis. Spun hematocrits were determined 3 to 4 weeks after infection with FVP. The results were analyzed by Student *t* test through the use of Microsoft Excel 2003 software (Redmond, WA).

### Fetal liver transplantation

We intercrossed Balb/cByJ Epor<sup>+/-</sup>;Tg(GFP) mice to obtain embryonic day 12.5 Epor<sup>-/-</sup>;Tg(GFP) embryos. Epor<sup>-/-</sup>;Tg(GFP) embryos were identified by their pale appearance and fluorescence with a GFP flashlight (BLS, Budapest, Hungary). We harvested fetal livers and prepared a single-cell suspension. Fetal liver cells ( $5 \times 10^5$  to  $2 \times 10^6$  cells) were injected into the tail vein of lethally irradiated (9 Gy [900 rad]) adult C.B6-*Fv2<sup>tr</sup>* mice. Four weeks after transplantation, we analyzed GFP expression in circulating leukocytes, platelets, and erythrocytes by flow cytometry. Transplant recipients were T-cell depleted prior to Friend virus infection through administration of 2 intraperitoneal injections of anti-CD4 (rat monoclonal GK1.5) and anti-CD8 (rat monoclonal 2.43) antibody. T-cell depletion has been reported to increase the susceptibility of mice to Friend disease.<sup>26</sup>

### Immunohistochemistry

For GFP, gp55, TER119, and GATA1 immunohistochemistry, we used rabbit anti-GFP antibody (Molecular Probes, Eugene, OR), goat anti-

Rauscher leukemia virus gp69/71 antibody (ViroMed, Camden, NJ), rat anti-mouse TER119 antibody (BD Pharmingen, San Jose, CA), and goat anti-mouse GATA1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Following blocking for endogenous peroxidase, endogenous biotin, and nonspecific sera, slides were sequentially incubated with primary antibody (rabbit anti-GFP, 1:200; goat anti-Rauscher gp69/71, 1:8000; rat anti-mouse TER119, 1:500; or goat anti-mouse GATA1, 1:75) for 30 minutes (60 minutes for GATA1), biotinylated secondary antibody (1:200) for 10 minutes (30 minutes for GATA1), streptavidin conjugated to horseradish peroxidase for 10 minutes, and diaminobenzidine for 5 minutes. Tris-buffered saline was used for washes in between each step. For GATA1, heat-induced epitope retrieval was performed at more than 95°C for 30 minutes prior to staining. Slides were counterstained with hematoxylin and examined with a Nikon E600 microscope with Nikon Plan Apo 2×/0.10, 10×/0.45, and 40×/0.95 objective lenses (Nikon, Tokyo, Japan). Photomicrographs were taken with a Nikon DXM1200 digital camera. ACT-1 version 2.63 (Nikon) software was used to acquire images, and image contrast was adjusted with Adobe Photoshop 6.0 software (Adobe Systems, San Jose, CA).


### Immunoprecipitation

For immunoprecipitation and Western blotting, anti-STAT5A, anti-STAT5B, and anti-pTyr 4G10 antibody were purchased (Upstate, Lake Placid, NY). Anti-Janus kinase-2 (anti-JAK2) antibody was previously described.<sup>27</sup> Friend virus–infected erythroblasts were isolated<sup>28</sup> and cultured in complete Friend virus medium (30% fetal bovine serum, 1% deionized bovine serum albumin, 0.001% monothio glycerol, 2 mM glutamine, and penicillin-streptomycin in IMDM) without EPO for 8 hours. Erythroblasts were stimulated with EPO (epoetin alfa, 4 U/mL; Amgen, Thousand Oaks, CA) for 15 minutes. Whole-cell lysates were prepared from  $2 \times 10^7$  cells in 0.5 mL RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 7.5) with protease inhibitors (aprotinin 5 μg/mL, leupeptin 5 μg/mL, pepstatin 1 μg/mL, 1 mM DTT, and 0.5 mM PMSF). Immunoprecipitation and Western blotting were performed in accordance with standard procedures.<sup>29</sup>

## Results

### The distal EPOR and STAT5 are not required for Friend virus–induced erythroblastosis

First, we considered the possibility that an interaction between sf-STK and the EPOR causes phosphorylation of cytoplasmic tyrosine residues of the EPOR and the activation of downstream signal transduction pathways. To test this hypothesis, we infected 3 mutant strains of mice with Friend virus. The EporH strain expresses a truncated EPOR, which lacks the distal 108 amino acids of the EPOR and all but the most proximal tyrosine residue (Y<sup>343</sup>). This tyrosine residue is sufficient for STAT5 activation.<sup>19</sup> The EporHM strain is identical to the EporH strain except that Y<sup>343</sup> has been mutated to phenylalanine. Due to the lack of cytoplasmic tyrosine residues, the EporHM strain is unable to activate STAT5 in response to EPO stimulation.<sup>19</sup> The STAT5-deficient strain contains targeted mutations of the 2 isoforms of STAT5 (Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup>).<sup>18</sup> Epor<sup>H/H</sup>, Epor<sup>HM/HM</sup>, and Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup> mice were susceptible to Friend virus–induced erythroblastosis (Figure 1A-C). Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup> mice showed less splenic enlargement than wild-type mice, but their spleens were still significantly larger than those of uninfected mice ( $P < .001$ ). Histologic sections from all 3 strains showed that splenic tissue was replaced with immature erythroblasts. The immature erythroid phenotype was confirmed by immunohistochemistry, which showed that most of the cells expressed GATA1 but not the late erythroid marker TER119 (Supplemental Figure S1, available at the *Blood* website; see the Supplemental Figure link at the top of the online article). Compared with wild-type and the EporH strain, splenic erythroblasts



**Figure 1. The distal EPOR and STAT5 are not required for Friend virus–induced erythroblastosis.** (A) Photograph of spleens from FVA-infected mice. Mouse strains are indicated at the top. Infection with Friend virus is indicated at the bottom (FVA). (B) Photomicrograph of spleen from Friend virus–infected EporHM mouse, stained with hematoxylin and eosin. Original magnification  $\times 400$ . (C) Spleen weights of FVA-infected mice in grams. The mouse strains are indicated at the bottom. Stat5 (-/-) denotes the Stat5a<sup>-/-</sup>;Stat5b<sup>-/-</sup> strain. The spleen weights of uninfected mice are provided as a control (no FV). Error bars represent standard deviation (Stat5 (-/-), EporH, EporHM,  $P < .001$ ). (D) Percent transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)–positive cells in the spleens of FVA-infected mice (Stat5 (-/-),  $P = .07$ ; EporH,  $P > .10$ ; EporHM,  $P = .10$ ).

from the EporHM and STAT5-deficient strains had a slightly elevated rate of apoptosis (Figure 1D).


**The EPOR is required for Friend virus–induced erythroblastosis, but not for gp55-mediated erythroid proliferation**

Next, we considered whether the EPOR might be entirely dispensable for susceptibility to Friend virus–induced erythroblastosis. To


test this possibility, we transplanted Epor<sup>-/-</sup> fetal liver cells into lethally irradiated adult mice. To provide transplant recipients, we backcrossed Fv2<sup>rr</sup> mice to a Balb/cByJ background to create a new congenic strain (C.B6-Fv2<sup>rr</sup>). C.B6-Fv2<sup>rr</sup> mice are histocompatible with donor fetal liver cells and resistant to Friend disease at the Fv2 locus. Mice containing a targeted mutation of the Epor were crossed with (H-2K<sup>b</sup>)-GFP transgenic mice to allow identification of donor-derived cells in transplant recipients.<sup>20</sup> Epor<sup>-/-</sup>;Fv2<sup>ss</sup>;Tg(GFP) fetal liver cells were transplanted into lethally irradiated C.B6-Fv2<sup>rr</sup> mice and bone marrow reconstitution assessed by the percentage of GFP-positive leukocytes and platelets (Figure 2A). As expected, the percentage of GFP-positive erythrocytes was very low (less than 1%). The mice were T-cell depleted to increase their susceptibility to Friend disease<sup>26</sup> and infected with Friend virus. The infected mice failed to develop enlarged spleens; however, microscopic examination showed that foci of immature erythroblasts were present (Figure 2B-G; Supplemental Figure S1). The cells in these foci stained with antibody against GFP, indicating they were donor-derived Epor<sup>-/-</sup>;Fv2<sup>ss</sup>;Tg(GFP) erythroid cells. They also stained with antibody against Rauscher gp69/71 antigen, which recognizes gp55,<sup>30</sup> indicating that they expressed the virally encoded oncoprotein. These results show that gp55 can support erythroid proliferation in the absence of the EPOR, but the EPOR is required for erythroblastosis to develop.

**The murine EPOR is not required for Friend virus–induced erythroblastosis**

To further assess the role of the EPOR in Friend virus–induced erythroblastosis, we exploited the existence of a species-specific interaction between gp55<sub>p</sub> and the EPOR. gp55<sub>p</sub> supports factor-independent Ba/F3-cell proliferation but only in the presence of the murine EPOR. The human EPOR is ineffective in this context.<sup>31</sup> We studied mice with a targeted mutation of the murine Epor that were transgenic for the human EPOR (Epor<sup>-/-</sup>;Tg(EPOR)).<sup>21</sup>



**Figure 2. The EPOR is not required for gp55-mediated erythroid proliferation.** GFP-positive Fv2<sup>ss</sup>;Epor<sup>-/-</sup> fetal liver cells were transplanted into Fv2<sup>rr</sup> recipients. (A) Flow cytometry was performed 4 weeks after transplantation to assess bone marrow reconstitution. Three subpanels correspond to granulocytes (i), platelets (ii), and erythrocytes (iii). The percentage of GFP-positive cells is indicated by the number above the line. (B-G) Photomicrographs of FVA-infected spleens. The sections in panels B, D, and F were stained with hematoxylin and eosin. The sections in panels C and E were stained with anti-GFP antibody and counterstained with hematoxylin. The section in panel G was stained with Rauscher anti-gp69/71 antibody. Original magnifications  $\times 20$  (B-C),  $\times 400$  (D-E), and  $\times 100$  (F-G).




**Figure 3. The murine EPOR is not required for Friend virus–induced erythroblastosis.** (A) Southern blot of genomic DNA from the progeny of *Epor*<sup>-/-</sup>;Tg(EPOR) × Balb/cByJ *Epor*<sup>+/-</sup> mice. The parents contained different targeted mutations of the *Epor*<sup>24,25</sup> which are indicated by the arrowheads (Epor KO-1 and Epor KO-2). Bands corresponding to the germ-line band and the human EPOR transgene (Tg(EPOR)), are indicated. Genotypes: lane 1, *Epor*<sup>+/-</sup>;Tg(EPOR); lane 2, wild type; lane 3, *Epor*<sup>-/-</sup>;Tg(EPOR). (B) Spleen weights of FVA-infected mice in grams. Genotypes are indicated at the bottom. *Epor*<sup>+/-</sup> and *Epor*<sup>+/-</sup> genotypes are grouped together as (+/-). Error bars represent standard deviations.


Murine EPOR deficiency in these mice is rescued by the human EPOR transgene, and EPOR signaling is essentially normal. *Epor*<sup>-/-</sup>;Tg(EPOR) mice were bred for one generation to a Friend virus–susceptible background (Balb/cByJ). An incidental consequence of our breeding strategy was the *Epor*<sup>-/-</sup>;Tg(EPOR) mice used in our studies contained 2 different targeted mutations of the *Epor*<sup>24,25</sup>. To ensure a proper genotype, we identified mice that lacked a germ-line murine *Epor* band by Southern blotting (Figure 3A). *Epor*<sup>-/-</sup>;Tg(EPOR) mice were fully susceptible to Friend virus–induced erythroblastosis (Figure 3B). Thus, the murine EPOR, which is essential for gp55-mediated Ba/F3-cell proliferation, is not required for Friend virus–induced erythroblastosis.

#### STAT5 activation is required for Friend virus–induced polycythemia

The underlying cause of FVP-induced polycythemia is the ability of gp55<sub>p</sub> to support EPO-independent terminal erythroid differentiation.<sup>32</sup> To see if this effect is dependent on gp55<sub>p</sub>-mediated activation of the EPOR, we examined the susceptibility of our mutant strains of mice to FVP-induced polycythemia. Following infection with FVP, wild-type, *Epor*<sup>H/H</sup>, and *Epor*<sup>-/-</sup>;Tg(EPOR) mice developed polycythemia, whereas *Epor*<sup>HM/HM</sup> and *Stat5a*<sup>-/-</sup>; *Stat5b*<sup>-/-</sup> mice showed minimal change or developed anemia (Figure 4). Thus, STAT5, which is inactive or absent in *Epor*<sup>HM/HM</sup> and *Stat5a*<sup>-/-</sup>; *Stat5b*<sup>-/-</sup> mice, respectively, has a role in FVP-induced polycythemia. To determine the effect of FVA and FVP on downstream targets of EPOR signaling, Friend virus–infected erythroblasts were purified by gravity sedimentation.<sup>28</sup> In FVA-



**Figure 4. STAT5 activation is required for Friend virus–induced polycythemia.** Hematocrits of different strains of mice are shown at baseline (pre-FVP) and 3 to 4 weeks after infection with FVP (post-FVP). The mouse strains and genotypes are indicated at the top. In each panel, the pre-FVP hematocrits are shown on the left and the post-FVP hematocrits on the right with a line connecting the values. Low hematocrit values were occasionally caused by internal bleeding.



**Figure 5. FVP constitutively activates JAK2 and STAT5.** Whole-cell extracts of Friend virus–infected erythroblasts were immunoprecipitated with anti-JAK2 (top group) or anti-STAT5A (bottom group) antibody and Western blotted. The antibody used for the Western blot is indicated to the left of the panels. The strain of mice, strain of Friend virus, and stimulation with erythropoietin are indicated at the top.

infected erythroblasts, in the absence of EPO there was faint JAK2 and no STAT5A tyrosine phosphorylation (Figure 5). EPO induced JAK2 and STAT5A phosphorylation. In FVP-infected erythroblasts, in the absence of EPO there was constitutive tyrosine phosphorylation of JAK2, STAT5A, and STAT5B (Figure 5 and data not shown). EPO induced an increase in JAK2 phosphorylation and a greater increase in STAT5A phosphorylation. We obtained similar results with erythroblasts isolated from *Epor*<sup>-/-</sup>; Tg(EPOR) mice. In FVP-infected erythroblasts from *Epor*<sup>HM/HM</sup> mice there was constitutive JAK2 activation, but no STAT5A activation, in the absence or presence of EPO. Together, these results indicate that FVP causes polycythemia by constitutively activating the EPOR and STAT5.

#### Discussion

Friend virus differs from most acutely oncogenic retroviruses in that it lacks a mutated cellular protooncogene. Instead, the transforming gene in Friend virus encodes a mutated retroviral envelope protein, gp55. Previous studies suggested that the mechanism of Friend virus–induced erythroblastosis involves constitutive activation of the EPOR. One study showed that gp55-mediated activation of the EPOR supports Ba/F3-cell proliferation.<sup>9</sup> Another showed that recombinant SFFV, engineered to express a constitutively active mutant of the EPOR, causes Friend-like disease and erythroleukemia.<sup>33</sup> On the other hand, our laboratory has shown that susceptibility to Friend virus–induced erythroblastosis depends on expression of a truncated receptor tyrosine kinase, sf-STK.<sup>14</sup> Because the previous studies utilized cell lines<sup>9</sup> or enforced expression of a mutated receptor,<sup>33</sup> we sought to establish the in vivo significance of gp55-mediated activation of the EPOR.

Through the use of mutant strains of mice, we showed that Friend virus–induced erythroblastosis does not depend on an interaction between sf-STK and the distal EPOR; nor does it require STAT5 activation. The diminished splenomegaly in the STAT5-deficient mice suggests that STAT5 may contribute to the development of erythroblastosis, but STAT5 is not essential, because it is not activated in the susceptible *Epor*<sup>HM</sup> strain. Also, our results do not exclude the possibility that an interaction between the EPOR and sf-STK could result in the phosphorylation of sf-STK by JAK2. Recently, it was reported that phosphorylation of full-length STK by JAK2 can support the proliferation of erythroid cells.<sup>34</sup>


To determine whether the EPOR itself was required for susceptibility to Friend virus–induced erythroblastosis, we transplanted *Epor*<sup>-/-</sup>; *Fv2*<sup>sls</sup>; Tg(GFP) fetal liver cells into *Fv2*<sup>slr</sup> mice. Following infection, the transplant recipients did not develop

erythroblastosis; however, because the target cell for Friend virus is EPO responsive<sup>35</sup> and therefore potentially underrepresented, the failure of these mice to develop overt disease was not unexpected. Also, their spleens contained foci of EPOR-deficient erythroblasts, which expressed gp55, demonstrating that the EPOR is not essential for gp55-mediated erythroid proliferation. Another approach we took was to exploit a species-specific interaction between gp55 and the EPOR. The murine EPOR, but not the human EPOR, is able to support gp55<sub>p</sub>-mediated Ba/F3-cell proliferation.<sup>31</sup> Indeed, the structural basis for this difference has been localized to a single amino acid in the transmembrane domain of the EPOR.<sup>36</sup> We found that mice expressing the human EPOR instead of the murine EPOR were fully susceptible to Friend virus-induced erythroblastosis. Surprisingly, infection of these mice with FVP also caused constitutive phosphorylation of JAK2 and STAT5 and the development of polycythemia. Thus, the human EPOR is activated by gp55<sub>p</sub> in these mice and supports terminal differentiation. Differences in the mechanism of human EPOR activation between Ba/F3 cells and primary erythroid cells remain to be resolved.

There is evidence that constitutive activation of the EPOR can support erythroid proliferation and transformation. In addition to constitutively active mutants of the EPOR that cause erythroleukemia, there are deletion mutants of gp55<sub>p</sub> that circumvent Fv2 restriction.<sup>37</sup> These mutants activate the EPOR in Ba/F3 cells and cause an attenuated form of Friend disease in Fv2<sup>s/s</sup> and Fv2<sup>r/r</sup> mice. However, they fail to interact with sf-STK and are poor inducers of EPO-independent erythroid bursts *in vitro*.<sup>38</sup> We showed that gp55<sub>p</sub> causes constitutive phosphorylation of JAK2 and STAT5, which raises the possibility that activation of the EPOR could contribute to gp55<sub>p</sub>-mediated erythroid proliferation. Any effect of gp55<sub>p</sub> on EPOR signaling, however, is insufficient to cause Friend disease in the absence of sf-STK (ie, in Fv2<sup>r/r</sup> mice). Furthermore, gp55<sub>A</sub>, which minimally activates JAK2 and does not activate STAT5, is comparably effective at inducing erythroblastosis. Given the requirement for sf-STK, we conclude that Friend virus-induced erythroblastosis is primarily caused by gp55-mediated activation of sf-STK. Consistent with that interpretation, gp55 constitutively activates sf-STK,<sup>38</sup> and gp55-mediated erythroid colony formation depends on sf-STK signaling.<sup>39</sup>

## References

- Friend C. Cell free transmission in adult Swiss mice of a disease having the character of a leukemia. *J Exp Med*. 1957;105:307-318.
- Ben-David Y, Bernstein A. Friend virus-induced erythroleukemia and the multistage nature of cancer. *Cell*. 1991;66:831-834.
- Ney PA, D'Andrea AD. Friend erythroleukemia revisited. *Blood*. 2000;96:3675-3680.
- Berger SA, Sanderson N, Bernstein A, Hankins WD. Induction of the early stages of Friend erythroleukemia with helper-free Friend spleen focus-forming virus. *Proc Natl Acad Sci U S A*. 1985;82:6913-6917.
- Wolff L, Ruscetti S. Malignant transformation of erythroid cells *in vivo* by introduction of a nonreplicating retrovirus vector. *Science*. 1985;228:1549-1552.
- Aizawa S, Suda Y, Furuta Y, et al. Env-derived gp55 gene of Friend spleen focus-forming virus specifically induces neoplastic proliferation of erythroid progenitor cells. *EMBO J*. 1990;9:2107-2116.
- Mirand EA. Murine viral-induced polycythemia. *Ann N Y Acad Sci*. 1968;149:486-496.
- Chung SW, Wolff L, Ruscetti SK. Transmembrane domain of the envelope gene of a polycythemia-inducing retrovirus determines erythropoietin-independent growth. *Proc Natl Acad Sci U S A*. 1989;86:7957-7960.
- Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. *Nature*. 1990;343:762-764.
- Best S, LeTissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. *Nature*. 1996;382:826-829.
- Ikeda H, Laigret F, Martin MA, Repaske R. Characterization of a molecularly cloned retroviral sequence associated with Fv-4 resistance. *J Virol*. 1985;55:768-777.
- Lilly F. Fv-2: identification and location of a second gene governing spleen focus response to Friend leukemia virus in mice. *J Natl Cancer Inst*. 1970;45:163-169.
- Geib RW, Dizik M, Anand R, Lilly F. Infection and transformation of Fv-2rr erythropoietin cells with Friend virus. *Virus Res*. 1987;8:327-333.
- Persons DA, Paulson RF, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. *Nat Genet*. 1999;23:159-165.
- Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, stk, derived from enriched hematopoietic stem cells. *Blood*. 1994;83:3160-3169.
- Wu H, Klingmuller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem cell factor receptors. *Nature*. 1995;377:242-246.
- Wu H, Klingmuller U, Acurio A, Hsiao JG, Lodish HF. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. *Proc Natl Acad Sci U S A*. 1997;94:1806-1810.
- Teglund S, Mckay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. *Cell*. 1998;93:841-850.
- Zang HS, Sato K, Nakajima H, et al. The distal region and receptor tyrosines of the Epo receptor are nonessential for *in vivo* erythropoiesis. *EMBO J*. 2001;20:3156-3166.
- Dominici M, Tadjali M, Kepes S, et al. Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. *Genesis*. 2005;42:17-22.



**Figure 6. Mechanism of Friend virus–induced erythroblastosis and polycythemia.** gp55 of the anemia- (gp55<sub>A</sub>) or polycythemia-inducing (gp55<sub>P</sub>) strains of Friend virus activates sf-STK, causing uncontrolled erythroid proliferation and erythroblastosis. gp55<sub>P</sub> activates the EPOR, JAK2, and STAT5, causing deregulated erythroid differentiation and polycythemia.

We found that gp55<sub>p</sub>-mediated activation of the EPOR and STAT5 are required for Friend virus-induced polycythemia. JAK2 and STAT5 were constitutively phosphorylated in FVP-infected, wild-type erythroid cells. JAK2 but not STAT5 was phosphorylated in FVP-infected, Epor<sup>HM</sup> erythroid cells, and loss of STAT5 activity effectively converted FVP from a polycythemia- to an anemia-inducing strain. Also, STAT5 deficiency impairs EPO-dependent differentiation of FVA-infected erythroblasts (P.A.N., unpublished data, April 18, 2002). Thus, EPOR signaling, and specifically STAT5 activation, has a role in promoting the differentiation of Friend virus-infected erythroblasts. In summary, our results show that gp55 can activate sf-STK and the EPOR with distinct biologic effects (Figure 6). Activation of sf-STK by gp55<sub>A</sub> or gp55<sub>P</sub> causes uncontrolled erythroid proliferation and erythroblastosis, whereas activation of the EPOR by gp55<sub>P</sub> causes EPO-independent terminal differentiation and polycythemia.

## Acknowledgments

We appreciate the efforts of the Flow Cytometry Laboratory and the Animal Resources Center of St Jude Children's Research Hospital. We thank Len Zon and Frank Costantini for providing Epor knock-out mice and Maurice Bondurant and Alan Bernstein for providing FVA and FVP. We thank Janet Partridge for helpful discussions.

21. Yu XB, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. *Blood*. 2001;98:475-477.
22. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. *Immunity*. 1999;10:249-259.
23. Ihle JN. The Stat family in cytokine signaling. *Curr Opin Cell Biol*. 2001;13:211-217.
24. Kieran MW, Perkins AC, Orkin SH, Zon LI. Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. *Proc Natl Acad Sci U S A*. 1996;93:9126-9131.
25. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. *Genes Dev*. 1996;10:154-164.
26. Behringer RR, Dewey MJ. Cellular site and mode of Fv-2 gene action. Conditional protection of Fv-2ss cells by admixture with Fv-2rr cells. *Exp Hematol*. 1989;17:330-334.
27. Silvennoinen O, Witthuhn BA, Quelle FW, et al. Structure of the murine Jak2 protein tyrosine kinase and its role in interleukin-3 signal transduction. *Proc Natl Acad Sci U S A*. 1993;90:8429-8433.
28. Koury MJ, Sawyer ST, Bondurant MC. Splenic erythroblasts in anemia-inducing Friend disease: a source of cells for studies of erythropoietin-mediated differentiation. *J Cell Physiol*. 1984;121:526-532.
29. Harlow E, Lane D. *Antibodies: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1988.
30. Ruscetti SK, Linemeyer D, Field J, Troxler D, Scolnick EM. Characterization of a protein found in cells infected with the spleen focus-forming virus that shares immunologic cross reactivity with the gp70 found in mink cell focus-inducing virus particles. *J Virol*. 1979;30:787-798.
31. Showers MO, Demartino JC, Saito Y, D'Andrea AD. Fusion of the erythropoietin receptor and the Friend spleen focus-forming virus gp55 glycoprotein transforms a factor-dependent hematopoietic cell line. *Mol Cell Biol*. 1993;13:739-748.
32. Hankins WD, Troxler D. Polycythemia-inducing and anemia-inducing erythroleukemia viruses exhibit differential erythroid transforming effects in vitro. *Cell*. 1980;22:693-699.
33. Longmore GD, Lodish HF. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. *Cell*. 1991;67:1089-1102.
34. van den Akker E, van Dijk T, Parren-van Amelsvoort M, et al. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. *Blood*. 2004;103:4457-4465.
35. Kost TA, Koury MJ, Hankins WD, Krantz SB. Target cells for Friend virus-induced erythroid bursts in vitro. *Cell*. 1979;18:145-152.
36. Constantinescu SN, Liu XD, Beyer W, et al. Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. *EMBO J*. 1999;18:3334-3347.
37. Kozak SL, Hoatlin ME, Ferro FE, et al. A Friend virus mutant that overcomes Fv-2rr host resistance encodes a small glycoprotein that dimerizes, is processed to cell surfaces, and specifically activates erythropoietin receptors. *J Virol*. 1993;67:2611-2620.
38. Nishigaki K, Thompson D, Hanson C, Yugawa T, Ruscetti S. The envelope glycoprotein of Friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk. *J Virol*. 2001;75:7893-7903.
39. Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH. Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. *Oncogene*. 2002;21:3562-3570.